角膜擦伤局部疼痛控制:系统评价与荟萃分析
该系统评价与荟萃分析纳入33项研究(31项RCT、2项队列研究),共4167例角膜擦伤患者,评估局部麻醉药、NSAIDs、睫状肌麻痹剂、类固醇、压迫包扎和绷带接触镜(BCL)的疗效与安全性。仅局部NSAIDs证据充分,显示24小时(SMD -0.69,95%CI -0.98至-0.41)和48小时(SMD -0.56,95%CI -1.02至-0.10)疼痛评分显著降低,口服镇痛药使用减少53%(95%CI 34%至67%)。局部麻醉药、睫状肌麻痹剂、压迫包扎和BCL对疼痛评分或口服镇痛药使用无显著差异,类固醇无研究。无干预导致愈合延迟或并发症显著增加,但压迫包扎无效且可能增加并发症风险。
要点
- 局部NSAIDs是唯一有充分证据的干预,可显著降低角膜擦伤24小时疼痛评分(SMD -0.69,95%CI -0.98至-0.41)和48小时疼痛评分(SMD -0.56,95%CI -1.02至-0.10)。
- 局部NSAIDs使口服镇痛药使用减少53%(95%CI 34%至67%),优于对照。
- 局部麻醉药、睫状肌麻痹剂、压迫包扎和BCL对疼痛评分或口服镇痛药使用无显著差异,证据不足。
- 压迫包扎无效且可能增加并发症风险,不推荐用于疼痛控制。
- 无干预导致愈合延迟或并发症显著增加,但罕见并发症需更大样本RCT验证。
适用人群与场景
- 角膜擦伤患者(急诊常见眼科就诊原因),纳入比较局部疼痛治疗与另一治疗或对照的原研究。
诊断标准与关键阈值
- 原文未提及
处置流程与药物剂量
- 原文未提及
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 系统评价与荟萃分析,纳入33项研究(31项RCT、2项队列研究),共4167例角膜擦伤患者,评估局部麻醉药、NSAIDs、睫状肌麻痹剂、类固醇、压迫包扎和BCL。仅局部NSAIDs证据充分:24小时疼痛评分SMD -0.69(95%CI -0.98至-0.41),48小时SMD -0.56(95%CI -1.02至-0.10),口服镇痛药使用减少53%(95%CI 34%至67%)。局部麻醉药、睫状肌麻痹剂、压迫包扎和BCL无显著差异,
证据类型、等级与局限
- 系统评价与荟萃分析,遵循PRISMA指南,方案注册于PROSPERO(CRD42020201288),使用GRADE方法评估证据质量。仅局部NSAIDs证据充分,其他干预证据不足。局限:部分干预研究数量少,罕见并发症需更大样本RCT验证。
对床旁实践的改变
- 支持急诊使用局部NSAIDs控制角膜擦伤疼痛并减少口服镇痛药需求;不推荐压迫包扎用于疼痛控制;局部麻醉药、睫状肌麻痹剂、类固醇和BCL证据不足,不能常规推荐。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Corneal abrasions are common ophthalmic presentations to emergency departments. Among emergency physicians and ophthalmologists, there are highly variable practice patterns with regard to management of resultant pain and discomfort. The goal of this study was to review and analyze the efficacy and safety of topical pain therapies for corneal abrasions, including topical anesthetics, nonsteroidal anti-inflammatory drugs (NSAIDs), cycloplegics, steroids, pressure patching, and the use of a bandage contact lens (BCL).
METHODS: The review followed the Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) guidelines. The protocol was established a priori and published on PROSPERO (CRD42020201288). MEDLINE, EMBASE, CENTRAL, and Web of Science were searched until December 31, 2020. Primary studies comparing topical pain therapies to another therapy or control were included. Primary outcomes included percentage of corneal abrasions healed at 24, 48, and 72 hours, as well as pain control at 24 and 48 hours. Secondary outcomes included use of oral analgesia and incidence of complications. Risk of bias was assessed using validated tools. Quality of evidence was assessed using the GRADE methodology.
RESULTS: Overall, 33 studies (31 randomized controlled trials [RCTs], two cohort studies) comprising 4,167 patients with corneal abrasions were analyzed. Only the data for topical NSAIDs were of adequate evidence from which to draw conclusions; topical NSAIDs demonstrated significantly reduced pain scores at 24 hours (standardized mean differences [SMD] -0.69, 95% CI = -0.98 to -0.41) and 48 hours (SMD = -0.56, 95% CI = -1.02 to -0.10) as well as 53% (95% CI = 34% to 67%) lower oral analgesia use compared to control. Based on available data, topical anesthetics, cycloplegics, patching, and the use of a BCL did not result in any significant difference in pain scores or use of oral analgesia, while no studies examined topical steroids. No interventions resulted in healing delays or significantly higher rates of complications compared to controls.
CONCLUSIONS: There was strong evidence to support that topical NSAIDs reduce pain associated with corneal abrasions in the first 48 hours and the need for oral analgesia. The existing evidence was insufficient to support or refute the use of topical anesthetics, cycloplegics, steroids, or BCL for pain control in corneal abrasions. Pressure patching was ineffective at pain reduction and may increase the risk of complications. Delays in healing or other complications were not significantly different between any intervention or control for simple, uncomplicated corneal abrasions; however, larger RCTs are required to identify any differences in rare complications.
参考来源
- Yu CW, Kirubarajan A, Yau M, et al. Topical pain control for corneal abrasions: A systematic review and meta-analysis. Acad Emerg Med. 2021. PMID: 33508879. doi:10.1111/acem.14222
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。